Related Experiment Video
Updated: Feb 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Practical Considerations for Antibodies in Myeloma
Jacob P Laubach1, Niels van de Donk1, Faith E Davies1
1From the Department of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; International Myeloma Foundation, North Hollywood, CA.
Monoclonal antibodies like daratumumab and elotuzumab improve multiple myeloma treatment outcomes. These therapies offer safety benefits and work well with existing myeloma drugs.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- Multiple myeloma treatment has advanced with new therapies.
- Monoclonal antibodies offer improved patient outcomes and safety.
Purpose of the Study:
- Review the use of monoclonal antibodies in multiple myeloma.
- Discuss current indications, challenges, and future directions for daratumumab and elotuzumab.
Main Methods:
- Literature review of clinical studies and guidelines.
- Analysis of safety profiles and efficacy data.
- Exploration of emerging drug combinations and novel antibodies.
Main Results:
- Daratumumab and elotuzumab are effective in multiple myeloma management.
- These antibodies show synergy with immunomodulatory drugs and proteasome inhibitors.
- Emerging combinations and new antibodies are under development.
Conclusions:
- Monoclonal antibodies have significantly improved multiple myeloma treatment.
- Daratumumab and elotuzumab represent key advancements in myeloma therapy.
- Ongoing research promises further therapeutic innovations.
Related Concept Videos
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...
Transmission Line Design Considerations
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Special considerations while measuring pulse
Energy Considerations in Open Channel Flow

